A detailed explanation of how much a box of Krazati currently costs and the price differences of different versions

Adagrasib (Krazati, chemical name Adagrasib) is an oral small molecule targeted drug targeting the KRAS G12C mutation. It has not yet been officially launched in mainland China, so domestic patients cannot purchase it directly through local hospitals or pharmacies. For patients in need of medicine, they currently mainly rely on overseas drug purchasing channels, such as cross-border e-commerce, international medical institutions or personal purchasing. Since it involves cross-border transportation and imported drug management, the purchase process needs to comply with relevant policies and regulations, and pay attention to drug authenticity identification and formal channel selection.

In the U.S. market, the original drug adagrasib is developed and produced by Mirati Therapeutics and has been approved by the FDA for the treatment of specific KRAS G12C mutated tumors. The price of this version is very high, with the price of each box reaching more than 100,000 yuan. The specific price will vary depending on dosage specifications, sales channels and exchange rate fluctuations. Behind the high prices is the result of multiple factors such as innovative drug research and development costs, clinical trial investment, and pharmaceutical company pricing strategies.

Compared with the original drug, generic versions of adagrasibu have appeared in overseas markets, among which generic drugs produced in Laos are more common. The price of each box of the Lao version of adagrasibu is about more than 3,000 yuan, and the drug ingredients and main active ingredients are basically the same as the original drug, which greatly reduces the financial burden on patients. Since generic drugs must comply with local regulatory requirements in terms of production process, quality standards and consistency of efficacy, patients should still obtain them through reliable channels when making choices to ensure drug safety.

The price gap between different versions of adagrasib varies greatly, which is mainly affected by factors such as R&D investment, patent protection, market pricing policy, production costs and channel expenses. The high prices of original drugs reflect the value of innovative drugs and their market monopoly during the patent period; while generic drugs have rapidly lowered the threshold for drug use by virtue of their cost advantages. In the future, if adagrasib is approved in China and entered into the medical insurance list, its price is expected to drop significantly, thus benefiting more KRAS G12C mutation patients.

Reference materials:https://www.drugs.com/